Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

Inclusion Criteria: Screening Phase: * Age 21 or older. * Histologically proven stage I-III carcinoma of the breast. * Plan to receive adjuvant or neoadjuvant chemotherapy that includes weekly paclitaxel. * Eastern Cooperative Oncology Group performance status 0-2 (see Appendix B). * The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form. * Proficiency in English with the ability to speak and read English. Exclusion Criteria: * Known metastatic (stage IV) breast cancer involvement. * Pre-existing peripheral neuropathy within 28 days of screening consent * Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine. Intervention Phase: * Age 21 or older. * Histologically proven stage I-III carcinoma of the breast. * Receiving adjuvant or neoadjuvant chemotherapy that includes a taxane. * Eastern Cooperative Oncology Group performance status 0-2 * The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form. * Proficiency in English with the ability to speak and read English * While on neurotoxic chemotherapy, has developed NCI-CTC grade 2 CIPN Exclusion Criteria: * Known metastatic (stage IV) breast cancer involvement. * Pre-existing peripheral neuropathy within 28 days of screening consent. * Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.